Eve (US:EVEX) Seeking Alpha·2025-11-24 23:13Core Insights - Vivesto is undergoing a significant transformation, focusing on its project portfolio, particularly Paccal Vet and Cantrixil, amidst a capital raise [1] - The company has shifted from a broad R&D organization to a targeted oncology-driven biotech, applying advanced delivery technologies to meet medical needs in both human and veterinary medicine [4] Group 1 - Arwidsro has been a long-term owner of Vivesto, providing stability and capital that has facilitated the company's transformation [3] - The support from shareholders has allowed Vivesto to rebuild and refocus, resulting in a leaner and more agile organization [3] - Vivesto is now positioned for sustainable growth with a clear strategic direction and strong operational discipline [4]